Christopher Heylman received his Ph.D. in Biomedical Engineering from Case Western Reserve University. He also holds a B.S. in General Engineering with a concentration in Biomedical Engineering from Cal Poly, San Luis Obispo. He performed his graduate research on the transport limitations in engineered tissue constructs for orthopedic defects at the Cleveland Clinic Lerner Research Institute. Following his graduate studies, Dr. Heylman was a George E. Hewitt Foundation for Medical Research Postdoctoral Fellow at the University of California, Irvine. There, he worked as part of both the Edwards Lifesciences Center for Advanced Cardiac Technologies and the Laboratory for Fluorescence Dynamics developing microphysiological systems (vascularized tissues and organs on a chip) for high throughput drug screening. Prior to joining Cal Poly, Dr. Heylman founded and served as CEO of Velox Biosystems, a clinical diagnostic startup developing rapid tests for the detection of sepsis and antibiotic resistance that utilize a combination of microfluidics, fluorescent microscopy, and droplet based chemistry.
- Clinical Diagnostics / Lab on a Chip
- Stem Cells
- Tissue Engineering / Regenerative Medicine
- Tissues and Organs on a Chip